Literature DB >> 24696435

OXA β-lactamases.

Benjamin A Evans1, Sebastian G B Amyes.   

Abstract

The OXA β-lactamases were among the earliest β-lactamases detected; however, these molecular class D β-lactamases were originally relatively rare and always plasmid mediated. They had a substrate profile limited to the penicillins, but some became able to confer resistance to cephalosporins. From the 1980s onwards, isolates of Acinetobacter baumannii that were resistant to the carbapenems emerged, manifested by plasmid-encoded β-lactamases (OXA-23, OXA-40, and OXA-58) categorized as OXA enzymes because of their sequence similarity to earlier OXA β-lactamases. It was soon found that every A. baumannii strain possessed a chromosomally encoded OXA β-lactamase (OXA-51-like), some of which could confer resistance to carbapenems when the genetic environment around the gene promoted its expression. Similarly, Acinetobacter species closely related to A. baumannii also possessed their own chromosomally encoded OXA β-lactamases; some could be transferred to A. baumannii, and they formed the basis of transferable carbapenem resistance in this species. In some cases, the carbapenem-resistant OXA β-lactamases (OXA-48) have migrated into the Enterobacteriaceae and are becoming a significant cause of carbapenem resistance. The emergence of OXA enzymes that can confer resistance to carbapenems, particularly in A. baumannii, has transformed these β-lactamases from a minor hindrance into a major problem set to demote the clinical efficacy of the carbapenems.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24696435      PMCID: PMC3993105          DOI: 10.1128/CMR.00117-13

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  202 in total

1.  In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.

Authors:  Paul G Higgins; Thamarai Schneiders; Axel Hamprecht; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii.

Authors:  Stéphane Corvec; Laurent Poirel; Thierry Naas; Henri Drugeon; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

3.  ISAba825 controls the expression of the chromosomal bla(OXA-51-like) and the plasmid borne bla(OXA-58) gene in clinical isolates of Acinetobacter baumannii isolated from the USA.

Authors:  B S Lopes; L Al-Hassan; S G B Amyes
Journal:  Clin Microbiol Infect       Date:  2012-08-03       Impact factor: 8.067

4.  Intrapatient emergence of OXA-247: a novel carbapenemase found in a patient previously infected with OXA-163-producing Klebsiella pneumoniae.

Authors:  S Gomez; F Pasteran; D Faccone; M Bettiol; O Veliz; D De Belder; M Rapoport; B Gatti; A Petroni; A Corso
Journal:  Clin Microbiol Infect       Date:  2013-02-12       Impact factor: 8.067

5.  Detection of New Delhi metallo-β-lactamase (encoded by blaNDM-1) in Acinetobacter schindleri during routine surveillance.

Authors:  Patrick McGann; Michael Milillo; Robert J Clifford; Erik Snesrud; Lindsay Stevenson; Michael G Backlund; Helen B Viscount; Reyes Quintero; Yoon I Kwak; Michael J Zapor; Paige E Waterman; Emil P Lesho
Journal:  J Clin Microbiol       Date:  2013-04-03       Impact factor: 5.948

Review 6.  OXA-48-like carbapenemases: the phantom menace.

Authors:  Laurent Poirel; Anaïs Potron; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2012-04-11       Impact factor: 5.790

7.  OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.

Authors:  Paul G Higgins; Laurent Poirel; Marlene Lehmann; Patrice Nordmann; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

8.  Wide dissemination of GES-type carbapenemases in Acinetobacter baumannii isolates in Kuwait.

Authors:  Rémy A Bonnin; Vincent O Rotimi; Mona Al Hubail; Elise Gasiorowski; Noura Al Sweih; Patrice Nordmann; Laurent Poirel
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

9.  Eleven novel OXA-51-like enzymes from clinical isolates of Acinetobacter baumannii.

Authors:  B A Evans; S Brown; A Hamouda; J Findlay; S G B Amyes
Journal:  Clin Microbiol Infect       Date:  2007-09-11       Impact factor: 8.067

10.  Dissemination of imipenem-resistant Acinetobacter baumannii with new plasmid-borne bla(OXA-72) in Taiwan.

Authors:  Shu-Chen Kuo; Su-Pen Yang; Yi-Tzu Lee; Han-Chuan Chuang; Chien-Pei Chen; Chi-Ling Chang; Te-Li Chen; Po-Liang Lu; Po-Ren Hsueh; Chang-Phone Fung
Journal:  BMC Infect Dis       Date:  2013-07-13       Impact factor: 3.090

View more
  244 in total

Review 1.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology.

Authors:  Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

2.  Carbapenem-Susceptible OXA-23-Producing Proteus mirabilis in the French Community.

Authors:  Anaïs Potron; Didier Hocquet; Pauline Triponney; Patrick Plésiat; Xavier Bertrand; Benoit Valot
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Rapid and Consistent Evolution of Colistin Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa during Morbidostat Culture.

Authors:  Bianca Dößelmann; Matthias Willmann; Matthias Steglich; Boyke Bunk; Ulrich Nübel; Silke Peter; Richard A Neher
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  Characterization of the First OXA-10 Natural Variant with Increased Carbapenemase Activity.

Authors:  Stathis D Kotsakis; Carl-Fredrik Flach; Mohammad Razavi; D G Joakim Larsson
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

5.  First Report of the Carbapenemase Gene blaOXA-499 in Acinetobacter pittii.

Authors:  Roshan D'Souza; Naina Adren Pinto; Paul G Higgins; Insik Hwang; Dongeun Yong; Jongrak Choi; Kyoungwon Lee; Yunsop Chong
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

6.  The structure of a doripenem-bound OXA-51 class D β-lactamase variant with enhanced carbapenemase activity.

Authors:  Cynthia M June; Taylor J Muckenthaler; Emma C Schroder; Zachary L Klamer; Zdzislaw Wawrzak; Rachel A Powers; Agnieszka Szarecka; David A Leonard
Journal:  Protein Sci       Date:  2016-09-26       Impact factor: 6.725

7.  Role of the Hydrophobic Bridge in the Carbapenemase Activity of Class D β-Lactamases.

Authors:  Nichole K Stewart; Clyde A Smith; Nuno T Antunes; Marta Toth; Sergei B Vakulenko
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

8.  Structural Basis for Enhancement of Carbapenemase Activity in the OXA-51 Family of Class D β-Lactamases.

Authors:  Clyde A Smith; Nuno Tiago Antunes; Nichole K Stewart; Hilary Frase; Marta Toth; Katherine A Kantardjieff; Sergei Vakulenko
Journal:  ACS Chem Biol       Date:  2015-06-12       Impact factor: 5.100

9.  Resources for Genetic and Genomic Analysis of Emerging Pathogen Acinetobacter baumannii.

Authors:  Larry A Gallagher; Elizabeth Ramage; Eli J Weiss; Matthew Radey; Hillary S Hayden; Kiara G Held; Holly K Huse; Daniel V Zurawski; Mitchell J Brittnacher; Colin Manoil
Journal:  J Bacteriol       Date:  2015-04-06       Impact factor: 3.490

10.  Antimicrobial action of 1,10-phenanthroline-based compounds on carbapenemase-producing Acinetobacter baumannii clinical strains: efficacy against planktonic- and biofilm-growing cells.

Authors:  Roberta F Ventura; Anna Clara M Galdino; Livia Viganor; Ricardo P Schuenck; Michael Devereux; Malachy McCann; André L S Santos; Ana Paula F Nunes
Journal:  Braz J Microbiol       Date:  2020-07-31       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.